drug_type
RELEVANT_DRUG
intervention_type
Autologous TCR-T cell therapy
drug_description
Autologous TCR-engineered T-cell therapy targeting KRAS G12D presented by HLA-A*11:01 or HLA-A*11:02; infused cells recognize the KRAS G12D peptide–HLA complex on tumor cells and mediate cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a T-cell receptor that recognizes the KRAS G12D peptide presented by HLA-A*11:01 or HLA-A*11:02 on tumor cells. Upon antigen recognition, the engineered T cells become activated and mediate cytotoxic killing of KRAS G12D–positive tumor cells via TCR signaling, cytokine release, and perforin/granzyme pathways.
drug_name
AZD0240
nct_id_drug_ref
NCT06218914